NeoPhore, a cancer immune-oncology company, has formed a Scientific Advisory Board. It will be chaired by NeoPhore Scientific founder Professor Alberto Bardelli, Department of Oncology at the University of Torino, and deputy director of the Candiolo Cancer
Institute-IRCCS, Torino, Italy. In addition to his role in founding NeoPhore, Professor Bardelli also co-founded Horizon Discovery and he is the president elect of the European Association for Cancer Research (EACR).
The other members of the advisory board are:
- Luis Alberto
Diaz Jr: an internationally recognized physician-scientist and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital. Dr. Diaz directed clinical studies used for FDA approval of the PD-1 checkpoint inhibitor Keytruda (pembrolizumab) as indicated for any cancer with defective DNA mismatch repair. - Bert Vogelstein: a landmark figure in cancer research, Clayton Professor of Oncology and Pathology and Co-Director of the Ludwig Cancer at the Johns Hopkins Kimmel Cancer Center and Founder of Papgene Inc.
- Ken Kinzler: a pioneer of cancer genetics and genomics and Professor of Oncology and Co-Director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center.
- Ashok Venkitaraman: an international leader in cancer biology, the Ursula Zoellner Professor of Cancer Research at the University of Cambridge and the Director of the Medical Research Council (MRC) Cancer Unit.
